Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)

Summary

Drug therapy in patients with chronic low back pain is a major challenge for physicians. One of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient. Usually one of the classes of pain medication is given to patients with a similar clinical picture, although different pain mechanisms may be responsible for this clinical picture.

Another reason for variable drug efficacy are genetic polymorphisms, this may be the reason why an unique drug produces different responses (from a lacking analgesic effect up to excessive effect or side-effects.

Quantitative sensory testing is a method that documents alterations in the pain perception system. Linking genetic polymorphisms to quantitative sensory testing may give us a tool for anticipation of drug efficacy.

Conditions

• Low Back Pain

Interventions

DRUG

Oxycodone 15mg

15mg single administration p.o.

DRUG

Clobazam

20mg single administration p.o.

DRUG

Imipramine

75mg single administration p.o.

DRUG

Tolterodine

1 mg single administration p.o.

Sponsors & Collaborators

• University of Bern

  collaborator OTHER

• University of Zurich

  collaborator OTHER

• Aalborg University

  collaborator OTHER

• Insel Gruppe AG, University Hospital Bern

  lead OTHER

Principal Investigators

• Michele Curatolo, Prof · University Hospital Bern, Switzerland

• Andreas Siegenthaler, Dr Med · University Hospital Bern, Switzerland

• Pascal H Vuilleumier, Dr Med · University Hospital Bern, Switzerland

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

TRIPLE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-07-31

Primary Completion

2015-04-30

Completion

2015-12-31

Countries

• Switzerland